The effects of a thromboxane synthase inhibitor, a prostacyclin analog and PGE1 on the nephritis of the NZB/W F1 mouse.
One hundred NZB/W F1 female mice were studied to compare the effects of a thromboxane synthase inhibitor (TSI), a stable prostacyclin analog (iloprost) and prostaglandin E1 (PGE1) in the evolution of the nephritis. At 10 weeks of age mice were randomly assigned to cohorts of 20 to receive either no treatment, vehicle control, PGE1, iloprost or TSI. Proteinuria, mortality, systemic blood pressure, renal immune complex deposition, urinary TX B2 and 6 keto PGF1 alpha levels were measured. Mice receiving PGE1 and iloprost had a significant delay in the onset of proteinuria and reduction in mortality at 40 weeks. The TSI treatment had no apparent effect on proteinuria or mortality. The amelioration of the nephritis was not associated with an alteration in immune complex deposition in survivors at 40 weeks. Although PGE1 and iloprost lessened the age related increase in urinary TX B2, increased the urinary 6 keto PGF1 alpha levels and the ratio of 6 keto PGF1 alpha to TX B2; so did the TSI. The PGE1 treated mice did experience a marked and persistent reduction in blood pressure but this was not observed in the iloprost- or the TSI-treated mice. All drugs tested reduced the age-related increase in thromboxane B2 but only the PGE1 and iloprost had a significant effect on the evolution of the nephritis.
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D000367:Age Factors; D000527:Alprostadil / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D011464:Epoprostenol / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D016285:Iloprost; D008181:Lupus Nephritis / Q000188:drug therapy; D051379:Mice; D008814:Mice, Inbred NZB; D008815:Mice, Inbred Strains; D009393:Nephritis / Q000188:drug therapy* / Q000401:mortality; D011507:Proteinuria / Q000188:drug therapy; D013929:Thromboxane B2 / Q000652:urine; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use
D001572:Benzofurans; D014665:Vasodilator Agents; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D000527:Alprostadil; D016285:Iloprost; C039936:furegrelate